Orchestra BioMed Holdings ( (OBIO) ) has shared an update.
On January 30, 2025, Orchestra BioMed Holdings appointed Christopher Cleary to its Board of Directors as a Class II director, a role anticipated to bolster the company’s strategic initiatives given Cleary’s extensive experience in mergers, acquisitions, and corporate development. Cleary’s appointment follows his influential tenure at Medtronic, where he played a pivotal role in key collaborations, including the strategic partnership between Medtronic and Orchestra BioMed. Concurrently, Eric A. Rose, M.D., resigned from the Board to transition into an Emeritus Board Member and Strategic Advisor role, enabling him to continue contributing his expertise to the company. The changes in the Board’s composition are expected to influence Orchestra BioMed’s strategic direction and reinforce its focus on advancing medical technologies through partnerships.
More about Orchestra BioMed Holdings
Orchestra BioMed Holdings is a biomedical innovation company focused on accelerating high-impact technologies to patients through risk-reward sharing partnerships with leading medical device companies. Their business model includes strategic collaborations, such as with Medtronic for atrioventricular interval modulation (AVIM) therapy for hypertension, and with Terumo for the Virtue Sirolimus AngioInfusion Balloon for artery disease treatment.
YTD Price Performance: 8.74%
Average Trading Volume: 101,037
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $212.1M
See more data about OBIO stock on TipRanks’ Stock Analysis page.